Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Other Accumulated Expenses (2016 - 2023)

Vistagen Therapeutics' Other Accumulated Expenses history spans 7 years, with the latest figure at $10000.0 for Q2 2023.

  • For Q2 2023, Other Accumulated Expenses changed N/A year-over-year to $10000.0; the TTM value through Jun 2023 reached $10000.0, changed N/A, while the annual FY2021 figure was $27800.0, 22.47% up from the prior year.
  • Other Accumulated Expenses for Q2 2023 was $10000.0 at Vistagen Therapeutics, down from $62600.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $62600.0 in Q3 2021 and bottomed at $5500.0 in Q4 2020.
  • The 4-year median for Other Accumulated Expenses is $13200.0 (2020), against an average of $18850.0.
  • The largest annual shift saw Other Accumulated Expenses plummeted 30.38% in 2020 before it skyrocketed 281.71% in 2021.
  • A 4-year view of Other Accumulated Expenses shows it stood at $7900.0 in 2019, then tumbled by 30.38% to $5500.0 in 2020, then skyrocketed by 1038.18% to $62600.0 in 2021, then crashed by 84.03% to $10000.0 in 2023.
  • Per Business Quant, the three most recent readings for VTGN's Other Accumulated Expenses are $10000.0 (Q2 2023), $62600.0 (Q3 2021), and $27800.0 (Q1 2021).